Summit Securities Group’s Procept Biorobotics PRCT Stock Holding History

Summit Securities Group’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$13K	Buy	+715	New	+$14.3K	﹤0.01%	771

Other funds holding PRCT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Bastion Asset Management Montreal, Canada $229M AUM 5.92% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return

C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Peregrine Capital Management Minneapolis, Minnesota $2.95B AUM 28.43% 1-Year Est. Return

Summit Securities Group's PRCT Position: Q3 2026 in Review

Summit Securities Group opened a new position in Procept Biorobotics (PRCT) in Q3 2026: 715 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #771 among its holdings.

113 funds tracked by Wall St. Rank hold PRCT as of Q3 2026.

Summit Securities Group held 715 shares of Procept Biorobotics worth $13K as of Q3 2026.
Procept Biorobotics was a new Summit Securities Group position in Q3 2026.
Procept Biorobotics made up ﹤0.01% of Summit Securities Group's portfolio in Q3 2026, its #771 holding.
113 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.